Protocol 016: Wk 24 Metabolic and Renal Outcomes Similar for Monthly Oral Islatravir vs Placebo as HIV PrEP in Phase IIa Study

February 13-16, 2022; Virtual
No clinically meaningful differences in metabolic and renal parameters observed between monthly oral placebo and islatravir for PrEP through 24 weeks.
Format: Microsoft PowerPoint (.ppt)
File Size: 191 KB
Released: February 16, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Cepheid
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck & Co., Inc.
ViiV Healthcare

Related Content

Analysis of new data from CROI 2022 provided by expert HIV faculty, from Clinical Care Options (CCO)

Daniel R. Kuritzkes, MD David A. Wohl, MD Released: March 14, 2022

Clinical Care Options (CCO) expert analysis of new data from CROI 2022, provided by expert HIV faculty

Monica Gandhi, MD, MPH Babafemi Taiwo, MBBS Released: March 7, 2022

Dr Jonah Musa discusses how long-acting ARVs can impact HIV prevention and management in Africa, from Clinical Care Options (CCO)

Jonah Musa, MBBS, MSCI, PhD Released: March 4, 2022

Expert discussion of data from the VISEND and 2SD studies presented at CROI 2022 on switching to INSTI-based regimens as second-line ART, from Clinical Care Options (CCO)

Brenda E. Crabtree Ramírez, MD Released: March 4, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings